Drug discovery, clinical and translational teams have no shortage of promising therapeutic opportunities. But how do you efficiently choose the right one to develop, while avoiding potential biological, safety and clinical risks? 

See how to systematically evaluate repurposing opportunities for a GLP-1 receptor agonist using causal biomedical knowledge graphs and evidence from over 6.8 million clinical trial records. We’ll use AI to help uncover new disease–target relationships, assess safety, learn from past clinical trials and find new indications that would otherwise be difficult to surface.